Skip to site menu Skip to page content

Soft Mist Inhalers: Lung Deposition Benefits for Respiratory Conditions

By Upperton Pharma Solutions
Biopharma companies are under continued pressure to respond to the global increase in acute respiratory conditions, with the global market for inhalation drug delivery devices expected to reach $20.7bn by 2031, growing at a compound annual growth rate (CAGR) of 4.4%. With direct delivery to target sites, rapid onset of action and a reduced risk of systemic side effects compared to oral therapies, the inhalation market is growing at a phenomenal rate.
Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Related Content